Climb Bio (CLYM)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from CLYM's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Climb Bio's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net income | -$47M | -$45M | -$35M | -$74M | -$60M |
| Free cash flow | — | — | -$21M | -$16M | -$55M |
| EPS (diluted) | -$4.24 | -$1.72 | -$1.30 | -$1.53 | -$0.88 |
| Operating margin | — | — | — | — | — |
Superinvestors who own CLYM
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by Climb Bio's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you. Every purchase since records began.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Jan 5, 2026 | Ra Capital Management, L.p. |
7,111 | $3.50 | $24,888 |
| Dec 12, 2025 | Ra Capital Management, L.p. |
101,462 | $2.86 | $290,181 |
| Dec 11, 2025 | Ra Capital Management, L.p. |
213,099 | $2.18 | $464,556 |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when CLYM trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Climb Bio insiders buying the stock?
3 open-market insider purchases of CLYM in the last 12 months, from SEC Form 4 filings.
Companies like Climb Bio
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 8, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.